Valeant Pharmaceuticals International Inc. is scheduled to report third-quarter earnings before the bell Tuesday and analysts are expecting another decline in profit and revenue.
New CEO Joseph Papa set reducing debt as a key goal for the company when it reported second-quarter earnings, unveiling a plan to sell assets and transform itself into a more conventional drugmaker. The company was forced to ask lenders to amend covenants on some of its borrowing earlier this year to avoid default.
Analysts will expect an update on a report last week by
“Although we question if this is the optimal time to...